PharmaCyte Biotech (PMCB) vs Silexion Therapeutics (SLXN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PharmaCyte Biotech is the larger company by market cap ($4.3 million vs $3.1 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMCB | SLXN |
|---|---|---|
| Share price | $0.3977 | $0.2146 |
| Market cap | $4.27M | $3.11M |
| 1-day change | -1.54% | -8.64% |
| EPS (TTM) | $-2.31 | $-27.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.51 | $40.70 |
| 52-week low | $0.3339 | $0.2141 |
| Distance from 52-week high | -73.66% | -99.47% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +2229.92% |
| Average volume | 205.72K | 9.90M |
| Shares outstanding | 10.74M | 14.47M |
| Employees | 2 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2 employees
About Silexion Therapeutics
SLXN stock →Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 13 employees
PMCB vs SLXN FAQ
Which is bigger, PharmaCyte Biotech or Silexion Therapeutics?
PharmaCyte Biotech (PMCB) is larger, with a market capitalization of $4.27M compared with $3.11M for Silexion Therapeutics (SLXN).
Are PharmaCyte Biotech and Silexion Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.